PI-RADS 2.1版在前列腺癌检测中的前瞻性评估
该前瞻性研究纳入110例连续登记患者,于2019年4月至9月行多参数MRI并按PI-RADSv2.1评分后行经直肠超声-MRI融合穿刺及12针系统穿刺,共评估171个病灶。前列腺癌总体检出率为43.3%(74/171),临床显著前列腺癌为33.3%(57/171);检出率随PI-RADSv2.1评分升高而增加。
要点
- PI-RADS 5分病灶前列腺癌检出率90.0%、临床显著癌80.0%,4分为51.9%和44.2%。
- PI-RADS 3分病灶前列腺癌检出率24.1%、临床显著癌14.8%,2分为20.0%和5.7%。
- 16例多参数MRI未见病灶(PI-RADS 1)患者中,前列腺癌检出率50.0%、临床显著癌18.8%。
关键影像表现/征象
- 共检出并评估171个病灶,中位大小1.1 cm;16例患者未检出病灶,仅行系统穿刺。
- 病灶PI-RADS分类为:1类1个、2类34个、3类54个、4类52个、5类30个。
- 组织病理学显示171个病灶中74个(43.3%)为前列腺癌、57个(33.3%)为临床显著前列腺癌。
诊断标准与关键数值
- 前列腺癌(Gleason分级分组>0)检出率:PI-RADS 2类20.0%、3类24.1%、4类51.9%、5类90.0%。
- 临床显著前列腺癌(Gleason分级分组>1)检出率:PI-RADS 1类0%、2类5.7%、3类14.8%、4类44.2%、5类80.0%。
- 16例多参数MRI表现正常(PI-RADS 1)患者中,前列腺癌检出率50.0%、临床显著前列腺癌检出率18.8%。
临床应用与阅片要点
- 按PI-RADSv2.1评分记录病灶类别,并以评分分层报告前列腺癌及临床显著前列腺癌的检出率。
- PI-RADS 1类且多参数MRI未见病灶者仅行系统穿刺,该组前列腺癌检出率50.0%、临床显著癌18.8%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to prospectively evaluate Prostate Imaging Reporting and Data and System version 2.1 (PI-RADSv2.1), which was released in March 2019 to update version 2.0, for prostate cancer detection with transrectal ultrasound-MRI fusion biopsy and 12-core systematic biopsy. SUBJECTS AND METHODS. This prospective study included 110 consecutively registered patients who underwent multiparametric MRI evaluated with PI-RADSv2.1 criteria followed by fusion biopsy and systematic biopsy between April and September 2019. Lesion-based cancer detection rates (CDRs) were calculated for prostate cancer (Gleason grade group, > 0) and clinically significant prostate cancer (Gleason grade group, > 1). RESULTS. A total of 171 lesions (median size, 1.1 cm) in 110 patients were detected and evaluated with PI-RADSv2.1. In 16 patients no lesion was detected, and only systematic biopsy was performed. Lesions were categorized as follows: PI-RADS category 1, 1 lesion; PI-RADS category 2, 34 lesions; PI-RADS category 3, 54 lesions; PI-RADS category 4, 52 lesions; and PI-RADS category 5, 30 lesions. Histopathologic analysis revealed prostate cancer in 74 of 171 (43.3%) lesions and clinically significant prostate cancer in 57 of 171 (33.3%) lesions. The CDRs of prostate cancer for PI-RADS 2, 3, 4, and 5 lesions were 20.0%, 24.1%, 51.9%, and 90.0%. The CDRs of clinically significant prostate cancer for PI-RADS 1, 2, 3, 4, and 5 lesions were 0%, 5.7%, 14.8%, 44.2%, and 80.0%. In 16 patients with normal multiparametric MRI findings (PI-RADS 1), the CDRs were 50.0% for PCa and 18.8% for clinically significant prostate cancer. CONCLUSION. This investigation yielded CDRs assessed with prospectively assigned PI-RADSv2.1 scores. CDRs increased with higher PI-RADSv2.1 scores. These results can be compared with previously published outcomes derived with PI-RADS version 2.0.
引用
- Walker SM, Mehralivand S, Harmon SA, et al. Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection. AJR Am J Roentgenol. 2020. PMID: 32877244. doi:10.2214/AJR.19.22679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。